Zevra Therapeutics’ (ZVRA) Buy Rating Reiterated at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $26.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 101.49% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Guggenheim upped their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Canaccord Genuity Group boosted their price target on Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, BTIG Research reissued a “buy” rating and issued a $27.00 price objective (up from $23.00) on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Trading Up 2.0%

NASDAQ ZVRA traded up $0.25 during trading on Tuesday, reaching $12.90. The company’s stock had a trading volume of 376,757 shares, compared to its average volume of 1,307,513. The stock has a market capitalization of $762.88 million, a PE ratio of 6.47 and a beta of 0.91. The business has a 50-day moving average price of $11.07 and a 200-day moving average price of $9.69. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $14.27.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, analysts expect that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth about $53,000. Russell Investments Group Ltd. grew its holdings in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the last quarter. Creative Planning bought a new position in Zevra Therapeutics in the 2nd quarter worth approximately $92,000. Finally, Quarry LP bought a new position in Zevra Therapeutics in the 3rd quarter worth approximately $103,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.